Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

The study, which is being offered when children have their pre-school vaccination, involves a finger prick and a few drops of blood.

Early diagnosis can help prevent the life-threatening illness that can occur if type 1 diabetes (T1D) is diagnosed late. Early treatment can avoid the need for intensive care and indeed any hospital admission, and reduce the stress that accompanies an unexpected diagnosis.

T1D is the commonest autoimmune disease of childhood, affecting one in 350 children. It is caused by the destruction of the insulin-producing cells in the pancreas, resulting in elevated blood sugar levels. This long-term condition results in life-long insulin dependence and increased risk of major health problems, such as heart disease, blindness and kidney failure.

In around a quarter of children with T1D (and in more than half diagnosed during the COVID-19 pandemic), the diagnosis is not made until they become severely unwell, in ‘diabetic ketoacidosis’ (DKA), which results in hospitalisation, and can cause shock, brain swelling and, if untreated, death.

One or two children die every year as a result of a late T1D diagnosis. Beth Baldwin’s son, Peter, was aged 13 when he died of DKA due to a late diagnosis.

Beth, from Cardiff, said: “I am very happy this study has been approved. If testing was standard eight years ago, I wouldn’t be participating now and Peter would still be here. Testing pre-school children will revolutionise type 1 diagnosis and save many lives. Awareness saves lives.

“I am hopeful of a positive outcome that leads to a UK-wide roll-out in the mission to prevent DKA diagnosis of T1 and any fatalities from this condition. This is part of Peter’s legacy.”

Dr Rachel Besser, a paediatric diabetes consultant at Oxford University Hospitals (OUH) and Chief Investigator on the study at the University of Oxford, said: “We now have an accurate test, which just requires a simple finger prick blood sample, that can identify children who will develop T1D before they get any symptoms. So far, the test is proving popular.”

Read the full story on the Department of Paediatrics website. 

Similar stories

Promising Marburg vaccine yet to be tested on humans due to lack of funding

Oxford University’s Professor Teresa Lambe, the designer of the vaccine, fears Marburg disease is ‘now being seen in places where it’s never been seen before’

Early life infection increases sensitivity to pain in newborn babies

Researchers from Oxford’s Department of Paediatrics have discovered that infection can increase a baby’s sensitivity to pain, which may last longer than the infection.

Oxford expands the Cartography collaboration with Janssen

The University of Oxford announced today that it has expanded a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Oxford scientist named Australian of the Year in the UK

The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.

Typhoid vaccine over 81% effective in tackling disease in Nepal

A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.